Monoclonal antibody - Anodyne Nanotech
Latest Information Update: 24 Sep 2025
At a glance
- Originator Anodyne Nanotech
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 23 Jul 2025 Monoclonal antibody - Anodyne Nanotech is available for licensing as of 23 Jul 2025. https://www.theheropatch.com/partners (Anodyne Nanotech pipeline, July 2025)
- 23 Jul 2025 Preclinical trials in Unspecified in USA (Transdermal) prior to July 2025 (Anodyne Nanotech pipeline, July 2025)
- 23 Jun 2025 Anodyne Nanotech has patents pending for microneedles and microneedle patches for transdermal drug delivery and methods of making and using the same in USA, Israel, Europe, South Korea, Japan, Australia, Mexico, Brazil, Canada and worldwide